256 related articles for article (PubMed ID: 30618353)
1. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States.
Teeple A; Ginsburg S; Howard L; Huff L; Reynolds C; Walls D; Ellis LA; Curtis JR
Curr Med Res Opin; 2019 Apr; 35(4):603-609. PubMed ID: 30618353
[TBL] [Abstract][Full Text] [Related]
2. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.
Teeple A; Ellis LA; Huff L; Reynolds C; Ginsburg S; Howard L; Walls D; Curtis JR
Curr Med Res Opin; 2019 Apr; 35(4):611-617. PubMed ID: 30712393
[TBL] [Abstract][Full Text] [Related]
3. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
Gibofsky A; Jacobson G; Franklin A; O'Hara-Levi S; Peyrin-Biroulet L; McGrath M; McCabe D
J Manag Care Spec Pharm; 2023 Apr; 29(4):343-349. PubMed ID: 36989450
[No Abstract] [Full Text] [Related]
4. The design of clinical trials to support the switching and alternation of biosimilars.
Faccin F; Tebbey P; Alexander E; Wang X; Cui L; Albuquerque T
Expert Opin Biol Ther; 2016 Dec; 16(12):1445-1453. PubMed ID: 27666115
[TBL] [Abstract][Full Text] [Related]
5. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
[TBL] [Abstract][Full Text] [Related]
7. Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.
Liu Y; Yang M; Garg V; Wu EQ; Wang J; Skup M
Adv Ther; 2019 Aug; 36(8):1851-1877. PubMed ID: 31168766
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
Feagan BG; Lam G; Ma C; Lichtenstein GR
Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
[TBL] [Abstract][Full Text] [Related]
9. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
Frantzen L; Cohen JD; Tropé S; Beck M; Munos A; Sittler MA; Diebolt R; Metzler I; Sordet C
Joint Bone Spine; 2019 Jul; 86(4):491-496. PubMed ID: 30659920
[TBL] [Abstract][Full Text] [Related]
10. A Survey Assessment of US Dermatologists' Perception of Biosimilars.
Barsell A; Rengifo-Pardo M; Ehrlich A
J Drugs Dermatol; 2017 Jun; 16(6):612-615. PubMed ID: 28686780
[TBL] [Abstract][Full Text] [Related]
11. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.
Sullivan E; Piercy J; Waller J; Black CM; Kachroo S
PLoS One; 2017; 12(4):e0175826. PubMed ID: 28410403
[TBL] [Abstract][Full Text] [Related]
12. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
[TBL] [Abstract][Full Text] [Related]
13. Perception of Biosimilar Biologics and Non-Medical Prescription Switching among Rheumatologists: A Saudi Society for Rheumatology Initiative.
Omair MA; Almadany R; Omair MA; Al Rayes H; Almalag HM; Alshamsan A
Saudi Pharm J; 2022 Jan; 30(1):39-44. PubMed ID: 35145344
[TBL] [Abstract][Full Text] [Related]
14. Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
Gasteiger C; Lobo M; Dalbeth N; Petrie KJ
Rheumatol Int; 2021 Jan; 41(1):163-171. PubMed ID: 32300866
[TBL] [Abstract][Full Text] [Related]
15. Short-term costs associated with non-medical switching in autoimmune conditions.
Gibofsky A; Skup M; Yang M; Mittal M; Macaulay D; Ganguli A
Clin Exp Rheumatol; 2019; 37(1):97-105. PubMed ID: 29998841
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
[TBL] [Abstract][Full Text] [Related]
18. Medical specialists' attitudes to prescribing biosimilars.
Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients.
Azevedo A; Bettencourt A; Selores M; Torres T
Acta Med Port; 2018 Sep; 31(9):496-500. PubMed ID: 30332374
[TBL] [Abstract][Full Text] [Related]
20. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
